Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ribomic, Inc. ( (JP:4591) ) has issued an update.
RIBOMIC, Inc. has announced promising results from a Phase 2 clinical trial of their drug umedaptanib pegol, designed to treat achondroplasia in pediatric patients. The trial showed that two patients experienced a significant increase in height growth velocity, with sustained efficacy over two years, potentially positioning RIBOMIC as a key player in developing treatments for this rare disease.
More about Ribomic, Inc.
RIBOMIC is a clinical-stage biopharmaceutical company focusing on the discovery and development of aptamer therapeutics, which are a type of nucleic acid medicine. The company utilizes its RiboART system to discover aptamer drugs aimed at addressing unmet medical needs, including eye diseases and rare childhood diseases such as short stature.
Average Trading Volume: 1,658,255
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen4.28B
See more data about 4591 stock on TipRanks’ Stock Analysis page.